Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cláudia Fagundes, MD, Pere Ginès, MD, PhD 

Similar presentations


Presentation on theme: "Cláudia Fagundes, MD, Pere Ginès, MD, PhD "— Presentation transcript:

1 Hepatorenal Syndrome: A Severe, but Treatable, Cause of Kidney Failure in Cirrhosis 
Cláudia Fagundes, MD, Pere Ginès, MD, PhD  American Journal of Kidney Diseases  Volume 59, Issue 6, Pages (June 2012) DOI: /j.ajkd Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

2 Figure 1 Serum creatinine concentration and mean arterial pressure in the patient described in the case vignette. American Journal of Kidney Diseases  , DOI: ( /j.ajkd ) Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

3 Figure 2 Pathogenesis of circulatory abnormalities in (left) compensated cirrhosis and (right) hepatorenal syndrome. Reproduced from Ginès & Schrier15 with permission of the Massachusetts Medical Society. American Journal of Kidney Diseases  , DOI: ( /j.ajkd ) Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

4 Figure 3 Survival of patients with cirrhosis according to type of hepatorenal syndrome (HRS). Reproduced from Alessandria et al46 with permission of John Wiley & Sons. American Journal of Kidney Diseases  , DOI: ( /j.ajkd ) Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

5 Figure 4 Proposed treatment algorithm for patients with type 1 hepatorenal syndrome (HRS). Abbreviation: MELD, Model for End-Stage Liver Disease. aPotentially reversible chronic liver diseases (alcoholic hepatitis, acute-on-chronic liver failure, etc) with no important associated comorbid conditions. American Journal of Kidney Diseases  , DOI: ( /j.ajkd ) Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

6 Figure 5 Proposed treatment algorithm for patients with type 2 hepatorenal syndrome (HRS). Abbreviations: SCr, serum creatinine; Tx, transplant. aOnly in patients without adverse reactions to diuretics and with sodium excretion under diuretic treatment of >30 mEq/d. bEither terliprerssin if available or norepinephrine; therapy with a combination of midrodine and octreotide also could be an option. American Journal of Kidney Diseases  , DOI: ( /j.ajkd ) Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions


Download ppt "Cláudia Fagundes, MD, Pere Ginès, MD, PhD "

Similar presentations


Ads by Google